EVOKE Returned a Clean No: Why the GLP-1 Null Result Matters More Than the Positive Ones

Why the hypothesis was reasonable

GLP-1 receptors are expressed in the brain. Observational work had suggested associations between GLP-1 use and lower dementia incidence. Metabolic dysfunction and neurodegeneration share pathways, and insulin signalling in the brain has been a research target for years — Alzheimer's has been described as type 3 diabetes in some literature, a framing that is loose but points at something real.

It was a serious hypothesis with a plausible mechanism, tested properly at scale with a two-year follow-up and nearly four thousand participants. That is how the process is supposed to work, and the answer is no.

A trial programme of that size represents a substantial investment. Its most useful output is a clear negative, and the field is better for having it than for continuing to cite observational associations.

Why this matters beyond Alzheimer's

The GLP-1 class has expanded into indication after indication — sleep apnoea, heart failure, kidney outcomes, osteoarthritis, addiction, fatty liver, and more. Much of that expansion is genuine, backed by trials with hard endpoints. Some of it is extrapolation from mechanism and observational association.

EVOKE is a useful corrective. A plausible mechanism plus an observational signal does not reliably predict a trial result, and this class is not a general-purpose intervention for every condition that correlates with metabolic dysfunction.

Reading it alongside the positive results

The same class produced SOUL in 2026 — oral semaglutide reducing major adverse cardiovascular events by 14% and heart-failure events by 22% in 9,647 high-risk patients with type 2 diabetes. Reading the two together is far more informative than reading either alone.

Where the class has hard-endpoint evidence it is genuinely strong. Where it has mechanism and association, it is a hypothesis. EVOKE is the demonstration that the two are not the same.

What a null result does not mean

It does not mean GLP-1s harm cognition. It does not close the question for other agents in the class, other doses, other populations or earlier disease stages. And it does not undermine the established indications, which rest on their own evidence.

It means this specific drug, at this dose, over two years, in this population, did not slow progression. That is a precise finding, and precision is what makes it useful.

The publication-bias point

Negative results are systematically under-reported, and a field where positive readouts move stock prices and prescribing has structural pressure in one direction. You will see this trial mentioned far less than any of the positive readouts from the same year, despite comparable size and rigour.

Our evidence policy treats null results as evidence of the same standing as positive ones. That is easy to state and harder to practise, because a null result generates almost no search demand — which is exactly why it belongs in coverage rather than only in a database.

What to take from it

If you are taking a GLP-1 for weight management or diabetes, this changes nothing about your treatment. If you were considering one partly in hope of cognitive benefit, this is the trial that addressed that hope directly, and the answer was no.

More broadly: when you see this class described as protective against a long list of conditions, the useful question is which of those has been tested. The list of tested-and-positive is real and growing. The list of tested-and-negative now has an entry, and that entry is what makes the first list credible.

What this costs, and where the money actually goes

Whatever the clinical question on this page, the financial one behind it is the same for almost every reader: this is an indefinite treatment, and the figure that matters is the monthly cost at a maintenance dose rather than the advertised entry price.

The Zepbound label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. Recommended maintenance dosages are 5, 10 and 15 mg, and increases are directed no sooner than every four weeks based on tolerability and response. So an advertised entry price describes roughly four weeks of a treatment most people take for years, and comparing providers on it compares them on a price nobody pays after month one.

Coverage beats every self-pay route by an order of magnitude. Establishing whether you qualify takes one phone call and is worth more than any price comparison.

Three mechanisms separate an advertised figure from what you pay. A required membership, which runs from $19.99 to $149 a month across the providers we track. Dose-escalation pricing, where the monthly cost rises as you titrate. And introductory rates, which apply to one month of an indefinite course — eleven programmes advertise one, and all are excluded from every ranking we publish.

The single question that resolves most of this is what you will pay at 10 mg, including every required fee. A provider who answers that plainly can be compared accurately, which is generally to the advantage of providers with nothing to hide.

How to check any claim on this page for yourself

Everything above should be checkable, and most of it is. Trial claims resolve to a registry entry and a peer-reviewed publication; regulatory claims resolve to an agency document; pricing claims resolve to a provider’s own published page read on a stated date.

Where we could not verify something, we say so rather than rounding it into confidence. Every pharmacy relationship on this site carries a reported rather than verified label, because not one provider has named its fulfilling pharmacy and registration class to us. That is the field we would weight most heavily if we had it, and it is the question worth putting first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.

Four checks take about ten minutes between them. Confirm your prescriber holds a current licence in your state, through that state’s medical board rather than through the provider’s own page. Confirm the fulfilling pharmacy is licensed, and registered as a nonresident pharmacy in your state if it ships from elsewhere. Search the pharmacy’s name against FDA warning letters and recall notices, both public. And ask for a certificate of analysis matched to the batch number on your vial.

None of that establishes that the medicine in your hand is safe. It establishes that the parties involved are inside the regulatory system and currently authorised, which is a floor rather than a guarantee. The honest framing is that you are reducing risk rather than eliminating it — and a provider unwilling to give you the names needed to run those checks has told you something worth knowing.